Xintian Pharmaceutical (002873) answered investors' concerns on the investor relations platform on January 13.

Investors: Is the COVID-19 clinical trial drug cevilostat developed by Shanghai Huilun Jiangsu Pharmaceutical, the majority shareholder holding company, currently operating normally?

Director of Xintian Pharmaceutical: Hello, Huilun Biotech, in which the company has a stake, is a high-tech enterprise dedicated to the development and technical service of small molecule innovative drugs and generic drugs. The “injectable cevirustat sodium” it produces has now been sold nationwide. It is the only drug with ALI/ARDS indications in the world. It is a novel anti-inflammatory storm proteinase inhibitor that mainly treats respiratory and critically ill patients with acute lung damage/acute respiratory distress syndrome. According to information, the operation and development of Huilun Biotech's chemical drug project has been steady and improving. Thank you for your interest in the company!

Investors: Hello, Secretary! “The company is applying with the park to expand production. It will invest 1 billion yuan during the year to build a new formulation production line that meets European and American cGMP requirements and a new high-level chemical formulation production base that meets EU standards. It can be put into operation by the end of next year at the latest.” This is May 2020 “Taizhou released a report on Shanghai Huilun, a shareholding company. May I ask: 1. What is the current progress of the production line and production base mentioned above? 2. In the face of the continuous spread of the epidemic in Europe and the US, is the company's injectable cevirustat sodium marketed in Europe and the US, and if so, does it require approval from the relevant local authorities?

Director of Xintian Pharmaceutical: Hello, after Huilun Biological Products, a participating company of the company, is listed one after another and large-scale sales are achieved, the existing production capacity can also basically meet current market demand. In order to further meet future market needs, related capacity expansion supporting construction projects will also be gradually promoted. According to reports, Huilun Biotech's products have not yet been sold abroad. Currently, the main goal is to quickly occupy and further expand the domestic market. According to relevant regulations, the sale of drugs abroad requires approval from the importing country or applying within the importing country and completing clinical trials in accordance with the prescribed procedures. Approval rules in different importing countries are different. Thank you for your interest in the company!

Investors: Hello, Secretary! There are a few questions to ask: 1. What is the status of COVID-19 injections for injectable cevilostatin from Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd., a subsidiary of Shanghai Huilun, in which the company is a shareholder? 2. What stage has Shanghai Huilun Jiangsu Pharmaceutical reached in expanding production lines and production bases in Europe and the US? 3. Is Shanghai Huilun Jiangsu Pharmaceutical's injectable cevirustat sodium for COVID-19 ready to be marketed in Europe and the US. If it wants to be marketed, does it require approval from the relevant local authorities?

Director of Xintian Pharmaceutical: Hello, Huilun Biotech, a shareholding company in the company, has successively obtained registration approvals for more than 10 drugs, including “civerastatin sodium for injection”. The products have now been marketed and sold on a large scale. Related capacity expansion supporting construction projects are also progressing gradually; according to reports, Huilun Biotech's products have not been sold abroad at present. Thank you for your interest in the company!

According to Xintian Pharmaceutical's 2021 three-quarter report, the company's main revenue was 745 million yuan, up 3754% year on year; Guimu's net profit was 889.33,500 yuan, up 45.66% year on year; after deducting non-net profit of 86.1777 million yuan, up 47.73% year on year; among them, in the third quarter of 2021, the company's main revenue for a single quarter was 291 million yuan, up 21.86% year on year; Guimu's net profit for the single quarter was 42.0961 million yuan, up 17.42% year on year; withholding non-net profit of 395.869 million yuan, up 16.91% year on year; debt ratio 42.53%, financial expenses of 1,1582,400 yuan, gross profit margin of 79.38%.

In the last 90 days, the stock was rated by 1 institution and bought 1 rating; the Securities Star valuation analysis tool shows that Xintian Pharmaceutical (002873) has a good company rating of 3 stars, a good price rating of 2 stars, and a comprehensive valuation rating of 2.5 stars. (Rating range: 1 to 5 stars, maximum 5 stars)

Xintian Pharmaceutical's main business: research and development, production and sales of proprietary Chinese medicine products for urological diseases, gynecology, and other diseases of complex etiology, to provide patients with safe and effective products.

The chairman of the company is Dong Dalun. Mr. Dong Dalun: Born in 1964, Chinese nationality, no permanent residency abroad, master's degree, senior engineer. Graduated from Nanjing Pharmaceutical University (now China Pharmaceutical University) in 1984 with a bachelor's degree in biopharmaceutics, and graduated from the China-Europe International Business School with an advanced master's degree in business administration (EMBA) in 2007. From 1984/7 to 1992/6, he served successively as an engineer and director of a biochemical pharmaceutical factory in Guiyang; from 1992/7 to 2002/12, he was the legal representative, manager, and executive director of Xintian Biotech from 2011/4 to 2011/4; Chairman and manager of Xintian Biotech Limited from 1995/8 to 2001/11; Chairman and executive director of Haitian Pharmaceutical since 20003; Chairman of the company from 2001/12 to 2005.4; Chairman and general manager of the company since 2005/5 ( From 2013/4 to 2014/12, he also served as Secretary of the Company's Board of Directors).

This article was compiled by the Securities Star Data Center based on public data. It does not constitute investment opinions or suggestions. If you have any questions, please contact us.